What it sells
Enabling next generation medicines. A comprehensive platform and…
Business model breakdown
Workflow: what inputs become what output?
VectorSelect platform runs massively parallel screens to engineer high-yield cell lines; Apex Suites for AAV, lentiviral and biologics production.
Economics: what it saves and how it charges
Licensing of high-performing cell lines and cell line optimization services; terms not published.
Distribution: how it reaches customers
Licensing and partnerships via business development (bd@64xbio.com).
Funding history and coverage
| Round date | Stage | Amount | Investors | Source |
|---|---|---|---|---|
| — | Y Combinator Summer 2018 | — | Y Combinator | ycombinator.com |
Profiles summarize public reporting and company websites. Business-model notes are MaxBC's reading of that material, not confirmed facts; unknowns are left blank rather than guessed. Updated 2026-10-12.